Brief: HBM Holdings Announces License Agreement With CSPC Nbp Pharmaceutical
10/10/2022 10:17
Oct 10 (Reuters) - Hbm Holdings Ltd 2142.HK :
* LICENSE AGREEMENT WITH CSPC NBP PHARMACEUTICAL FOR
BATOCLIMAB
(HBM9161)
* DEAL TO DEVELOP, MANUFACTURE & COMMERCIALIZE ANY
PHARMACEUTICAL
OR BIOLOGICAL PRODUCT THAT INCORPORATES BATOCLIMAB IN GREATER
CHINA
Source text for Eikon: ID:
Further company coverage: 2142.HK
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study